Triple combination of insulin glargine, sitagliptin and metformin in type 2 diabetes: the EASIE post-hoc analysis and extension trial.

  title={Triple combination of insulin glargine, sitagliptin and metformin in type 2 diabetes: the EASIE post-hoc analysis and extension trial.},
  author={Juliana Chung Ngor Chan and Pablo J Aschner and David R. Owens and Sylvie Picard and Maya Vincent and M. P. Dain and Val{\'e}rie Pilorget and Virginie Loizeau and Akram Salim Echtay and Vivian A. Fonseca},
  journal={Journal of diabetes and its complications},
  volume={29 1},
AIM We examined the effects of adding glargine to metformin-sitagliptin (MS+G) or sitagliptin to metformin-glargine (MG+S) therapy in type 2 diabetic persons uncontrolled after 24-week MS or MG dual therapy. METHODS Subjects with A1c≥7% on MS or MG treatment were respectively given glargine (0.2U/kg starting dose) or sitagliptin (100mg daily) for 12weeks. The primary endpoint was number of subjects attaining A1c goal defined as <7%. RESULTS After receiving 24-week MS or MG dual therapy in… Expand
The effect of combination therapy of insulin glargine, metformin, and sitagliptin on insulin secretion, insulin resistance, and metabolic parameters in obese subjects with type 2 diabetes.
Sitagliptin can improve diabetes control and induce modest weight loss in obese subjects poorly controlled on insulin glargine and metformin and can be a prerequisite of success of this combination therapy. Expand
Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial
Metformin/sitagliptin as baseline therapy, with the addition of a third oral antihyperglycemic agent, including glimepiride, gliclazide, repaglinide, or acarbose, was effective, safe and well-tolerated for achieving an HbA1c <7.0% goal in type 2 diabetic patients inadequately controlled with previous therapies. Expand
OptiMising therapy after MetfOrMin in type 2 diabetes
A well-designed prospective study of insulin glargine added to metformin and compared to oral antidiabetic agents in newly diagnosed patients over 6-8 years showed a neutral effect of this insulin on cardiovascular events, and potential concerns, particularly with regard to an increased risk of cancer, were set aside by this study. Expand
Insulin Other Hypoglycemic Drugs
This literature review includes studies, meta-analyses, and case reports on the use of insulin, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide (GLP-1) agonists (incretin mimetics), type 2 sodium-glucose cotransporter (SGLT-2) inhibitor, metformin, and sulfonylureas published from January 2015 to December 2015. Expand
uSIng A PreMIx InSulIn (BIASP 30) wIth A DPP-4 InhIBItor - whA t Are the f ACtS?
An important trial using a premix insulin (BIAsp 30) as the initial insulin in type 2 diabetes patients uncontrolled on oral agents provides evidence on the use of this type of insulin with (orExpand
Solutions thérapeutiques pour un patient diabétique de type 2 mal contrôlé sous une combinaison metformine plus gliptine
  • A. Scheen
  • Médecine des Maladies Métaboliques
  • 2019
La triple therapie orale metforminegliptine-gliflozine offre un ratio favorable, en termes d’efficacite, tolerance, facilite d”usage, adhesion du patient, et cout. Expand


Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial
The results support the option of addition of basal insulin in patients with type 2 diabetes inadequately controlled by metformin and suggest long-term benefits might be expected from the achievement of optimum glycaemic control early in the course of the disease. Expand
Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA1c value
In pre-specified analyses adjusting for the most recently measured HbA1c value, there was a substantial reduction in risk for confirmed hypoglycemia with sitagliptin compared to glipizide when added to ongoing metformin therapy in patients with T2DM. Expand
Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial
In elderly patients with type 2 diabetes linagliptin was efficacious in lowering glucose with a safety profile similar to placebo, and could inform treatment decisions for achieving individualised glycaemic goals with minimal risk in this important population of patients. Expand
Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial
Early intensive insulin therapy in patients with newly diagnosed type 2 diabetes has favourable outcomes on recovery and maintenance of beta-cell function and protracted glycaemic remission compared with treatment with oral hypoglycaemic agents. Expand
Use of anti-diabetic drugs and glycaemic control in type 2 diabetes-tThe Hong Kong Diabetes Registry.
In a clinic-based type 2 diabetic population, 39.7% attained glycemic target with HbA(1c)<7%. Expand
Basal insulin and cardiovascular and other outcomes in dysglycemia.
Although it reduced new-onset diabetes, insulin glargine also increased hypoglycemia and modestly increased weight and had a neutral effect on cardiovascular outcomes and cancers. Expand
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Although saxagliptin improves glycemic control, other approaches are necessary to reduce cardiovascular risk in patients with diabetes, and DPP-4 inhibition with saxgliptin did not increase or decrease the rate of ischemic events, though the rates of hospitalization for heart failure was increased. Expand
Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis
A systematic review and meta-analysis to assess the comparative safety and efficacy of all available classes of antihyperglycemic therapies in patients with type 2 diabetes inadequately controlled on metformin monotherapy found DPP-4 inhibitors and GLP-1 analogues achieved improvements in glycemic control similar to those of other second-line therapies, although they may have modest benefits in terms of weight gain and overall hypoglycemia. Expand
Management of type 2 diabetes: new and future developments in treatment.
  • E. Liao
  • Medicine
  • The American journal of medicine
  • 2012
To date, six classes of oral medication have been approved by the U.S. Food and Drug Administration for the treatment of type 2 diabetes and several new agents have recently been introduced or are in the development pipeline. Expand
The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach
An A1C and ABCD of glycaemia management in type 2 diabetes is proposed to determine appropriate glycaemic targets based on Age, Body weight, Complications and Disease Duration to guide clinicians in the use of therapeutic agents more effectively, efficiently and safely. Expand